Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Breast cancer

Breast cancer drug deemed too expensive in England has been approved in Scotland

Close up of the breast cancer drug, Kadcyla

Source: Dr P Marazzi / Science Photo Library

NHS Scotland has approved the use of breast cancer drug Kadcyla, which was rejected for use in England on the grounds that its benefits did not justify its cost.

NHS Scotland has approved the use of Kadcyla, a drug used to treat HER2-positive breast cancer, which makes it one of 18 countries to offer the drug. In December 2016, the National Institute for Health and Care Excellence (NICE) recommended Kadcyla to be withdrawn for use on the NHS in England on the grounds that, at £90,000 per year per patient, its benefits did not justify its cost.

As part of a campaign called ‘Unlock Kadcyla’, led by the charity Breast Cancer Now and four women with incurable secondary breast cancer, more than 13,000 people signed a petition which was presented to the Scottish Medicines Consortium (SMC) and Roche (the company that manufactures Kadcyla). Consequently, the decision was made to make the drug available in Scotland.

The treatment options for this type of breast cancer at this time are relatively limited. The SMC says that the drug will enable patients to spend more time with their families and, in some cases, return to work.

“This decision will transform treatment options for women with HER2 positive secondary breast cancer in Scotland,” says Mary Allison, director of the charity, which aims to eliminate death from the disease during the next few decades.

“Both the Scottish government and Breast Cancer Now share the same vision of making sure that by 2050 everyone who develops breast cancer will live.

“If we are to achieve this, we’ll need to ensure that patients in Scotland are able to access the best possible treatments - and today is a real step forward for women with HER2 positive disease.”

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202593

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Close up of the breast cancer drug, Kadcyla

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.